Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
To analyze the immunogenicity and safety of inactivated subunit quadrivalent influenza vaccine (QIV) versus trivalent influenza vaccine (TIV) in children and adolescents 3-17 years of age. In this phase III, multicenter, double-blind study, 1200 subjects were randomized to receive QIV (n = 402), or TIV with the B-strain of the Victoria lineage (n = 404) or Yamagata lineage (n = 394). The primary objective was to demonstrate non-inferiority of QIV to TIV for immunogenicity against shared influenza strains, based on post-vaccination hemagglutinin inhibition (HI) titers. Secondary objectives were to show superiority of QIV to TIV for immunogenicity against alternate-lineage B-strains, and to further characterize immune response by analyzing virus neutralization and neuraminidase inhibition titers. Reactogenicity and safety were also compared post-vaccination. QIV elicited a non-inferior response for shared strains (upper limits of the 95% confidence intervals for the HI geometric mean ratios [GMRs] of TIV/QIV < 1.5) and a superior response for alternate-lineage B-strains (HI GMRs of TIV/QIV < 1.0; p < 0.0001) versus TIV. Reporting rates of local and systemic adverse reactions were similar between vaccine arms. QIV had comparable immunogenicity to TIV for shared strains and superior immunogenicity to the alternate-lineage B-strains in TIV. Safety and tolerability profiles were comparable.